Holmes Biopharma, Inc.

Holmes Biopharma, Inc.

June 11, 2007 09:01 ET

Holmes Biopharma-Clinical Research Business Becomes Profitable

SCOTTSDALE, ARIZONA--(Marketwire - June 11, 2007) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB) is pleased to announce that it's majority owned subsidiary, Qualia Clinical Services Inc. ("Qualia") had its first profitable month of operations in May/07. Based on contracts committed at this time, sales will exceed $1 million dollars in June/07 and sales growth is expected to continue throughout the balance of 2007 and 2008.

"We are extremely pleased with the progress of Qualia, from startup to profitability in just 7 months. We have every reason to believe this growth trend will continue as we add capacity in Omaha and other new facilities this year," stated John Metcalfe, President of Holmes Biopharma, Inc.

About Holmes:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information